Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria.This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
CEFPODOXIME PROXETIL belongs to the group of antibiotic medicines called 'cephalosporins' used to treat a wide range of bacterial infections of the ear, nose, throat, lower respiratory tract, urinary tract, skin, and soft tissue.
Cefpodoxime proxetil is an antibiotic that is used to treat various bacterial infections such as tonsillitis, ear infections, throat infections, urinary tract infections (UTIs), bronchitis, and other infections. The antibiotic works by destroying the cell walls of bacteria. Side effects of cefpodoxime proxetil include diarrhea, nausea, abdominal pain, vomiting, skin rash, diaper rash, fever, muscle pain, allergic reactions, vaginitis, vaginal infections, itching, headaches, dizziness, and insomnia. Cefpodoxime may cause a condition called pseudomembranous colitis, a potentially serious bacterial infection of the colon caused by a bacterium called Clostridium difficile (C. difficile colitis).
Cefpodoxime is an oral, third-generation cephalosporin antibiotic available in various generic preparations. It is active against both Gram-positive and Gram-negative organisms with notable exceptions including Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is typically used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.
Cefpodoxime proxetil is an orally administered prodrug which is absorbed and de-esterified by the intestinal mucosa to release the third generation cephalosporin, cefpodoxime. Cefpodoxime is stable towards the most commonly found plasmid-mediated beta-lactamases and the drug has a broad spectrum of antibacterial activity encompassing both Gram-negative and Gram-positive bacteria, rendering it a possible option for empirical use in a wide range of community acquired infections in both adult and paediatric patients.